WHO Director-General Dr Tedros, in his regular media briefing yesterday, highlighted that today is World Refugee Day and highlighted the risks of COVID-19 for some of the world’s most vulnerable people. He also stressed the shared duty to do everything we can to prevent, detect and respond to transmission of COVID-19 among refugee populations.

The hydroxychloroquine arm of the Solidarity Trial, which seeks to find an effective COVID19 treatment, is being stopped. The decision is based on evidence from the Solidarity Trial, the UK's Recovery trial and a Cochrane review of other evidence on hydroxychloroquine. Data shows that hydroxychloroquine does not result in the reduction of mortality of hospitalised COVID-19 patients, when compared with standard of care. 

The investigation of a cluster of COVID-19 cases in Beijing associated with a wholesale market continues. As of 18 June, 10AM CEST, Chinese authorities have reported a total of 172 cases since 11 June, including 158 in Beijing, 10 linked cases in Hebei Province, 2 in Liaoning Province, 1 in Sichuan Province and 1 in Zhejiang Province. Three genetic sequences related to Xinfadi cluster have been uploaded to the GISAID database. WHO is closely monitoring the situation and is in close contact with national authorities in China.

Sábado 20 de junio. 14 horas.

Programa de optimización de antimicrobianos en tiempos de Covid-19

Modera: Dr. Gabriel Levy Hara.

Diserta: Dra.Pilar Retamar Gentil (España)

Dra. María Virginia Villegas (Colombia)

Gratis, abierto a la comunidad y sin inscripción previa.

En vivo en nuestro FACEBOOK LIVE 

Viernes 26 de junio. 18 horas.

Webinar: Autotest de VIH en contexto de pandemia.

Expone: Dra Adele Schwartz Benzaken.

Gratis, abierto a la comunidad y sin inscripción previa.

En vivo en nuestro FACEBOOK LIVE 

WHO welcomes initial clinical trial results from the United Kingdom that show dexamethasone, a corticosteroid, can be lifesaving for patients who are critically ill with COVID-19. According to preliminary findings shared with WHO, for patients on ventilators, the treatment was shown to reduce mortality by about one third, and for patients who only require oxygen, mortality was cut by about one fifth.